OncoTherapy Science (TSE:4564) FCF Margin %: -105.92% (As of Mar. 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.03
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science FCF Margin %?

OncoTherapy Science TSE:4564 +5.00% 50 FCF Margin % is -105.92% as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.03 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 948 Biotechnology companies, OncoTherapy Science ranks worse than 55.49% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoTherapy Science's Free Cash Flow for the six months ended in Mar. 2026 was 円-398.9 Mil. OncoTherapy Science's Revenue for the six months ended in Mar. 2026 was 円376.6 Mil. Therefore, OncoTherapy Science's FCF Margin % for the quarter that ended in Mar. 2026 was -105.92%.

As of today, OncoTherapy Science's current FCF Yield % is -11.76%.

The historical rank and industry rank for OncoTherapy Science's FCF Margin % or its related term are showing as below:

TSE:4564' s FCF Margin % Range Over the Past 10 Years
Min: -1630.68   Med: -381.34   Max: -70.52
Current: -121.82


During the past 13 years, the highest FCF Margin % of OncoTherapy Science was -70.52%. The lowest was -1630.68%. And the median was -381.34%.

TSE:4564's FCF Margin % is ranked worse than
55.49% of 948 companies
in the Biotechnology industry
Industry Median: -83.535 vs TSE:4564: -121.82


OncoTherapy Science FCF Margin % Related Terms


OncoTherapy Science FCF Margin % Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science FCF Margin % Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -219.32 -70.52 -201.70 -108.70 -121.82

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.24 -257.13 -45.00 -135.69 -105.92

TSE:4564 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, OncoTherapy Science's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's FCF Margin % falls into.


TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OncoTherapy Science's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-984.967/808.53
=-121.82 %

OncoTherapy Science's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-398.929/376.639
=-105.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -105.92% mean?
OncoTherapy Science (TSE:4564) has a FCF Margin % of -105.92% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #526 out of 948 companies in the Biotechnology industry, placing it in the top 55.5%.
Is OncoTherapy Science's FCF Margin % too high?
OncoTherapy Science's current FCF Margin % is -105.92%. Based on the distribution chart, OncoTherapy Science ranks #526 out of 948 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #526 out of 948 companies for FCF Margin %. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current FCF Margin % is -105.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current FCF Margin % is -105.92%. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current FCF Margin % is -105.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • FCF Margin %: -105.92%
  • GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.03
GF Value